JVJason Valent

Jason Valent

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jason Valent has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Table 5 from Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention

    by Karie Feldman, Hong Li, Diana Basali, Faiz Anwer, Kimberly Bell, Beth Faiman, Raymond D. Jackson, Sandra Mazzoni, Kayona Moore, Natasha Patel, et al.

    Knowledge of multiple myeloma at the time of intervention and follow-up call.

  • Open Access

    Table 3 from Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention

    by Karie Feldman, Hong Li, Diana Basali, Faiz Anwer, Kimberly Bell, Beth Faiman, Raymond D. Jackson, Sandra Mazzoni, Kayona Moore, Natasha Patel, et al.

  • Open Access

    Table 4 from Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention

    by Karie Feldman, Hong Li, Diana Basali, Faiz Anwer, Kimberly Bell, Beth Faiman, Raymond D. Jackson, Sandra Mazzoni, Kayona Moore, Natasha Patel, et al.

  • Open Access

    Figure 1 from Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention

    by Karie Feldman, Hong Li, Diana Basali, Faiz Anwer, Kimberly Bell, Beth Faiman, Raymond D. Jackson, Sandra Mazzoni, Kayona Moore, Natasha Patel, et al.

    Educational brochure. The study team provided this brochure to community members who attended screening events. The brochure describes multiple myeloma, those at risk, and the symptoms and warning signs, as well as an infographic of the disease.

  • Open Access

    Table 1 from Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention

    by Karie Feldman, Hong Li, Diana Basali, Faiz Anwer, Kimberly Bell, Beth Faiman, Raymond D. Jackson, Sandra Mazzoni, Kayona Moore, Natasha Patel, et al.

  • Open Access

    Table 2 from Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention

    by Karie Feldman, Hong Li, Diana Basali, Faiz Anwer, Kimberly Bell, Beth Faiman, Raymond D. Jackson, Sandra Mazzoni, Kayona Moore, Natasha Patel, et al.

    Participant demographic characteristics (N = 199).

  • Open Access

    Data from Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention

    by Karie Feldman, Hong Li, Diana Basali, Faiz Anwer, Kimberly Bell, Beth Faiman, Raymond D. Jackson, Sandra Mazzoni, Kayona Moore, Natasha Patel, et al.

    Purpose:To address the lack of federal screening guidelines and a limited understanding of multiple myeloma among the public and some primary care providers, we created the first community-based multiple myeloma screening program and educational intervention.Patients and Methods:The academic cancer center partnered with community organizations to distribute an original brochure about multiple myeloma, draw blood to check for monoclonal protein, and survey screening participants about multiple myeloma knowledge and screening experiences. Any Black individual aged 50 or older was eligible. To examine multiple myeloma knowledge retention, study team members surveyed participants after at least 1 week had passed and screening results had been provided. The educational intervention also included continuing medical education (CME) about the early detection of multiple myeloma for healthcare professionals. Analysis utilized descriptive statistics and the McNemar test to assess differences between the initial and follow-up surveys.Results:From 2023 to 2024, across 22 screening events, 199 participants completed the screening. Among the 158 individuals who completed both surveys, correct responses increased on all items and increased significantly on items about multiple myeloma being a rare cancer of the blood (19%, P < 0.0001) and that individuals with monoclonal gammopathy of undetermined significance (MGUS) have an abnormal protein in the blood (12.1%, P = 0.002). Screening results identified 21 participants (11%) with MGUS. Forty-six healthcare providers engaged in three CME seminars.Conclusions:Participants retained knowledge about multiple myeloma gained during the screening. Improved health literacy about cancer risk for multiple myeloma may improve early detection, communication, and decision-making about cancer care.Significance:This study reveals that community members are receptive to multiple myeloma screening when healthcare professionals communicate with them about their risks and share knowledge about disease symptoms and incidence. Improved health literacy about cancer risk for multiple myeloma may improve early detection, communication, and decision-making about cancer care.

  • Open Access

    Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention

    by Karie Feldman, Hong Li, Diana Basali, Faiz Anwer, Kimberly Bell, Beth Faiman, Raymond D. Jackson, Sandra Mazzoni, Kayona Moore, Natasha Patel, et al.

    Purpose: To address the lack of federal screening guidelines and a limited understanding of multiple myeloma among the public and some primary care providers, we created the first community-based multiple myeloma screening program and educational intervention. Patients and Methods: The academic cancer center partnered with community organizations to distribute an original brochure about multiple myeloma, draw blood to check for monoclonal protein, and survey screening participants about multiple myeloma knowledge and screening experiences. Any Black individual aged 50 or older was eligible. To examine multiple myeloma knowledge retention, study team members surveyed participants after at least 1 week had passed and screening results had been provided. The educational intervention also included continuing medical education (CME) about the early detection of multiple myeloma for healthcare professionals. Analysis utilized descriptive statistics and the McNemar test to assess differences between the initial and follow-up surveys. Results: From 2023 to 2024, across 22 screening events, 199 participants completed the screening. Among the 158 individuals who completed both surveys, correct responses increased on all items and increased significantly on items about multiple myeloma being a rare cancer of the blood (19%, P < 0.0001) and that individuals with monoclonal gammopathy of undetermined significance (MGUS) have an abnormal protein in the blood (12.1%, P = 0.002). Screening results identified 21 participants (11%) with MGUS. Forty-six healthcare providers engaged in three CME seminars. Conclusions: Participants retained knowledge about multiple myeloma gained during the screening. Improved health literacy about cancer risk for multiple myeloma may improve early detection, communication, and decision-making about cancer care. Significance: This study reveals that community members are receptive to multiple myeloma screening when healthcare professionals communicate with them about their risks and share knowledge about disease symptoms and incidence. Improved health literacy about cancer risk for multiple myeloma may improve early detection, communication, and decision-making about cancer care.

  • Open Access

    Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy

    by Kirti Arora, Lara Soueid, Louis Williams, Jahanvi Grover, Diana Basali, Jack Khouri, Yuvraj Kaushal, Sandra Mazzoni, Rockey Dahiya, Beth Faiman, et al.

    Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by a heterogeneous risk of progression to overt multiple myeloma (MM). Historically managed with active surveillance, advances in risk stratification and the development of novel therapeutics have renewed debate regarding early intervention, particularly in patients with high-risk disease. We conducted a narrative review of clinical trials and observational studies evaluating early treatment versus observation in SMM. Outcomes assessed included progression-free survival (PFS), time to progression (TTP), overall survival (OS), treatment-related toxicity, and quality-of-life measures, alongside evolving diagnostic criteria and risk-stratification models that influence therapeutic decision-making. Early randomized trials using conventional cytotoxic therapy did not demonstrate a survival advantage and supported observation as the standard management approach. However, contemporary studies using novel agents have demonstrated improved disease control in selected high-risk populations. The QuiRedex and ECOG-E3A06 trials showed significant reductions in progression risk with lenalidomide-based therapy, and long-term follow-up suggests a potential overall survival benefit in Qui-Redex. The phase III AQUILA trial further demonstrated delayed progression with daratumumab in high-risk SMM using updated diagnostic criteria. Phase II studies evaluating combination regimens, including KRd-based and daratumumab-containing approaches, have reported high response rates and MRD negativity, although survival data remain immature. Importantly, many benefits reflect delayed biochemical or imaging-defined progression rather than prevention of symptomatic end-organ damage. Current evidence supports selective early intervention in carefully defined high-risk SMM populations; however, uncertainties remain regarding long-term survival benefit, optimal treatment duration, quality-of-life impact, and clonal evolution. Active surveillance with modern monitoring remains appropriate for many patients.

  • Open Access

    Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

    by Cindy Hsin-Ti Lin, Muhammad Junaid Tariq, Fauzia Ullah, Aishwarya Sannareddy, Farhan Khalid, Hasan Abbas, Abbas Bader, Christy Samaras, Jason Valent, Jack Khouri, et al.

    Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites. Common manifestations of MM include anemia, renal dysfunction, infection, bone pain, hypercalcemia, and fatigue. Despite numerous recent advancements in the MM treatment paradigm, current therapies demonstrate limited long-term effectiveness and eventual disease relapse remains exceedingly common. Myeloma cells often develop drug resistance through clonal evolution and alterations of cellular signaling pathways. Therefore, continued research of new targets in MM is crucial to circumvent cumulative drug resistance, overcome treatment-limiting toxicities, and improve outcomes in this incurable disease. This article provides a comprehensive overview of the landscape of novel treatments and emerging therapies for MM grouped by molecular target. Molecular targets outlined include BCMA, GPRC5D, FcRH5, CD38, SLAMF7, BCL-2, kinesin spindle protein, protein disulfide isomerase 1, peptidylprolyl isomerase A, Sec61 translocon, and cyclin-dependent kinase 6. Immunomodulatory drugs, NK cell therapy, and proteolysis-targeting chimera are described as well.